Unity Biotechnology Analysis
| UBXDelisted Stock | USD 0.16 0.01 6.67% |
Unity Biotechnology holds a debt-to-equity ratio of 1.297. With a high degree of financial leverage come high-interest payments, which usually reduce Unity Biotechnology's Earnings Per Share (EPS).
Asset vs Debt
Equity vs Debt
Unity Biotechnology's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Unity Biotechnology's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Unity Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Unity Biotechnology's stakeholders.
For most companies, including Unity Biotechnology, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Unity Biotechnology, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Unity Biotechnology's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that Unity Biotechnology's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Unity Biotechnology is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Unity Biotechnology to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Unity Biotechnology is said to be less leveraged. If creditors hold a majority of Unity Biotechnology's assets, the Company is said to be highly leveraged.
Unity Biotechnology is overvalued with Real Value of 0.15 and Hype Value of 0.16. The main objective of Unity Biotechnology delisted stock analysis is to determine its intrinsic value, which is an estimate of what Unity Biotechnology is worth, separate from its market price. There are two main types of Unity Biotechnology's stock analysis: fundamental analysis and technical analysis.
The Unity Biotechnology stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Unity Biotechnology is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day ( substitute day ), Independence Day. Unity Stock trading window is adjusted to America/New York timezone.
Unity |
Unity Stock Analysis Notes
About 17.0% of the company outstanding shares are owned by institutional investors. The company recorded a loss per share of 1.63. Unity Biotechnology had not issued any dividends in recent years. The entity had 1:10 split on the 20th of October 2022. Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California. Unity Biotechnology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 65 people. For more information please call Anirvan Ghosh at 650 416 1192 or visit https://unitybiotechnology.com.Unity Biotechnology Investment Alerts
| Unity Biotechnology is not yet fully synchronised with the market data | |
| Unity Biotechnology has some characteristics of a very speculative penny stock | |
| Unity Biotechnology has a very high chance of going through financial distress in the upcoming years | |
| Reported Net Loss for the year was (25.99 M) with loss before taxes, overhead, and interest of (12.06 M). | |
| Unity Biotechnology has about 64.51 M in cash with (20.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.26, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Unity Biotechnology Upcoming and Recent Events
Earnings reports are used by Unity Biotechnology to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Unity Market Capitalization
The company currently falls under 'Nano-Cap' category with a total capitalization of 3.44 M.Unity Biotechnology Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Unity Biotechnology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Unity Biotechnology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Unity Biotechnology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Unity Biotechnology Outstanding Bonds
Unity Biotechnology issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Unity Biotechnology uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Unity bonds can be classified according to their maturity, which is the date when Unity Biotechnology has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Unity Biotechnology Debt to Cash Allocation
As Unity Biotechnology follows its natural business cycle, the capital allocation decisions will not magically go away. Unity Biotechnology's decision-makers have to determine if most of the cash flows will be poured back into or reinvested in the business, reserved for other projects beyond operational needs, or paid back to stakeholders and investors.
Unity Biotechnology has 23.54 M in debt with debt to equity (D/E) ratio of 1.3, which is OK given its current industry classification. Unity Biotechnology has a current ratio of 4.05, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for Unity to invest in growth at high rates of return. Unity Biotechnology Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Unity Biotechnology's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Unity Biotechnology, which in turn will lower the firm's financial flexibility.Unity Biotechnology Corporate Bonds Issued
About Unity Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Unity Biotechnology prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Unity shares will generate the highest return on investment. We also built our delisted stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Delisted Stock such as Unity Biotechnology. By using and applying Unity Stock analysis, traders can create a robust methodology for identifying Unity entry and exit points for their positions.
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California. Unity Biotechnology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 65 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Unity Biotechnology to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Competition Analyzer Now
Competition AnalyzerAnalyze and compare many basic indicators for a group of related or unrelated entities |
| All Next | Launch Module |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Other Consideration for investing in Unity Stock
If you are still planning to invest in Unity Biotechnology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Unity Biotechnology's history and understand the potential risks before investing.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |